To include your compound in the COVID-19 Resource Center, submit it here.

Aromasin exemestane: Phase II data; Phase III; marketed as second-line therapy

In a Phase II study of patients with advanced estrogen-dependent breast cancer, Aromasin

Read the full 130 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE